HIV Infections Clinical Trials

46 studies are recruiting for hiv infections in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Precision Microbiota Interventions for Senoreduction Trial

   People with HIV who drink alcohol are at increased risk for accelerated aging biology, including increased immune senescence. This randomized, double-blind, crossover clinical trial evaluates two generally recognized as safe (GRAS) microbiota-targeted interventions on immune senescence biomarkers.

   Stage

   Phase 1

   Ages

   40 and older

   Site

   LSU Health, New Orleans, Louisiana

   Run by

   Louisiana State University Health Sciences Center in New Orleans

   See if you can join NCT07462767 on ClinicalTrials.gov

2. Dasatinib for HIV-1 Reservoir Reduction

   This study will test if the medicine dasatinib can lower the hidden amount of HIV in the body, called the HIV "reservoir." It will also check if dasatinib is safe and easy to take for people living with HIV who have a suppressed viral load while on antiretroviral therapy (ART). Adults 18 years or o…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Northwestern University CRS (Site # 2701), Chicago, Illinois

   Locations

   3 in total

   Run by

   National Institute of Allergy and Infectious Diseases (NIAID)

   See if you can join NCT07342491 on ClinicalTrials.gov

3. Screen Smart: Using Digital Health to Improve HIV Screening and Prevention

   The goal of this interrupted time series quasi-experimental design study is to implement universal opt- out HIV testing and linkage to HIV preventive care in 15-21 year old adolescents visiting the pediatric emergency department (ED). The main question[s] it aims to answer are: 1. What is the uptak…

   Stage

   Not phased

   Ages

   15 to 21

   Site

   Nationwide Children's Hospital, Columbus, Ohio

   Locations

   4 in total

   Run by

   Children's Hospital Medical Center, Cincinnati

   See if you can join NCT06003192 on ClinicalTrials.gov

4. Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention

   The goal of this observational study is to generate real-life information on the use of lenacapavir (LEN, YEZTUGO®, (YTG)) for pre-exposure prophylaxis (PrEP) across diverse clinical settings in the United States. The study will characterize how PrEP is initiated, used, and discontinued in routine …

   Stage

   Not phased

   Ages

   18 and older

   Site

   UAB 1917 Research Clinic, Birmingham, Alabama

   Locations

   44 in total

   Run by

   Gilead Sciences

   See if you can join NCT07473778 on ClinicalTrials.gov

5. A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants

   This study evaluates the PK, safety, and tolerability of a single increasing dose of VH4367310, a cabotegravir (CAB) prodrug, when administered intramuscularly in healthy adult participants 18 to 55 years of age.

   Stage

   Phase 1

   Ages

   18 to 55

   Site

   GSK Investigational Site, Glendale, California

   Locations

   2 in total

   Run by

   ViiV Healthcare

   See if you can join NCT07818915 on ClinicalTrials.gov

6. SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Families

   This study aims to prevent syndemic health conditions by decreasing acculturative stress and promoting resilience via SER Familia (Salud, Estrés y Resilencia en Familias/ Health, Stress, and Resilience in Families), a family-based intervention. SER Familia is a six-session intervention co-developed…

   Stage

   Not phased

   Ages

   12 to 100

   Site

   Duke School of Nursing, Durham, North Carolina

   Run by

   Duke University

   See if you can join NCT06627764 on ClinicalTrials.gov

7. Feasibility of HPV Testing With Mail-delivered Sample Collection Kits

   People living with human immunodeficiency virus (PLWH) have an estimated 1.6-6.0 times increased risk of developing oropharyngeal cancer (OPC) compared with individuals in the general population. 70% of OPCs are caused by human papillomavirus (HPV), and PLWH also have an increased prevalence of ora…

   Stage

   Not phased

   Ages

   35 and older

   Site

   University of California, San Francisco, San Francisco, California

   Run by

   University of California, San Francisco

   See if you can join NCT07087145 on ClinicalTrials.gov

8. A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed

   This study compares the efficacy, safety and tolerability of CAB ULA and RPV ULA administered with CAB long acting (LA) and RPV LA administered in adults and adolescents with HIV who are virologically suppressed on anti-retroviral therapy (ART).

   Stage

   Phase 3

   Ages

   12 and older

   Site

   GSK Investigational Site, Phoenix, Arizona

   Locations

   108 in total

   Run by

   ViiV Healthcare

   See if you can join NCT07650916 on ClinicalTrials.gov

9. El Camino HIV Prevention and Care Study

   The Camino Study evaluates a status-neutral, multi-level pilot intervention designed to improve HIV prevention and care engagement among Latin Americans with unmet HIV prevention and care needs. The intervention combines legal services with peer navigation to reduce fear of healthcare engagement, r…

   Stage

   Not phased

   Ages

   18 and older

   Site

   La Clínica del Pueblo, Washington D.C., District of Columbia

   Locations

   2 in total

   Run by

   American University

   See if you can join NCT07834853 on ClinicalTrials.gov

10. The TAIL-PrEP Study

    The goal of the TAIL-PrEP study is to understand how to support the safe discontinuation of injectable long-acting cabotegravir (cab-LA) and lenacapavir (LEN) while maximizing the public health impact of biomedical HIV prevention interventions. In Aim 1, the study will pilot test and assess the acc…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Columbia University Irving Medical Center / NewYork-Presbyterian Hospital, New York, New York

    Run by

    Columbia University

    See if you can join NCT06868641 on ClinicalTrials.gov

11. Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706

    The clinical schedule will consist of 3 injections of CD40.HIVRI.Env (VRIPRO) at weeks 0, 4, and 24.40 volunteers without HIV and in overall good health, aged 18 to 60 years, who previously participated in the HVTN 706 trial.

    Stage

    Phase 1

    Ages

    18 to 60

    Site

    Bridge HIV CRS, San Francisco, California

    Locations

    9 in total

    Run by

    National Institute of Allergy and Infectious Diseases (NIAID)

    See if you can join NCT06665646 on ClinicalTrials.gov

12. Couples Motivational Interviewing to Reduce Drug Use and HIV Risk in Vulnerable Male Couples

    This study utilizes a randomized controlled trial design to evaluate the efficacy of couples motivational interviewing (MI) to reduce the frequency and severity of illicit drug use and frequency of HIV transmission risk behavior (TRB). Participants are randomized to one of two conditions: couples M…

    Stage

    Not phased

    Ages

    18 to 55

    Site

    Hunter College, New York, New York

    Locations

    3 in total

    Run by

    Hunter College of City University of New York

    See if you can join NCT06307977 on ClinicalTrials.gov

13. SCOPE: Observational Study of the Consequences of the Protease Inhibitor Era

    SCOPE is an observational, prospective study of HIV-1 infected volunteers designed to provide a specimen bank of samples with carefully characterized clinical data. SCOPE specimens will be used to examine multiple questions involving virologic, immunologic, and host factors involved in HIV-1 infect…

    Stage

    Not phased

    Ages

    18 and older

    Site

    San Francisco General Hospital, San Francisco, California

    Run by

    University of California, San Francisco

    See if you can join NCT00187512 on ClinicalTrials.gov

14. Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT

    Among people living with HIV, heavy drinking increases the risk of heart disease and death. Studies suggest that alcohol changes the number and kind of bacteria in your gut and these changes increase the risk of heart disease and death. This randomized controlled trial will determine whether a pill…

    Stage

    Phase 2

    Ages

    18 to 89

    Site

    Vanderbilt University Medical Center, Nashville, Tennessee

    Run by

    Vanderbilt University Medical Center

    See if you can join NCT05288790 on ClinicalTrials.gov

15. Positive Peers Intervention Clinical Trial

    The goal of this clinical trial is to learn if the Positive Peers mobile app intervention increases rates of viral suppression in young (13-34 y/o) persons with HIV. Does use of the Positive Peers app improve viral suppression among young minority persons with HIV? What user characteristics are ass…

    Stage

    Not phased

    Ages

    13 to 34

    Site

    Northeast Valley Health Corporation, Van Nuys, California

    Locations

    7 in total

    Run by

    MetroHealth Medical Center

    See if you can join NCT06388109 on ClinicalTrials.gov

16. Screen2Prevent (S2P)

    Screen2Prevent is a study intended to improve HIV prevention and detection through implementation and evaluation of three different broad-scale HIV screening approaches a) targeted, b) universally offered opt-in, and c) universally offered opt-out in Emergency Departments (EDs) by leveraging digita…

    Stage

    Not phased

    Ages

    14 to 24

    Site

    University of South Florida, Tampa, Florida

    Locations

    5 in total

    Run by

    Westat

    See if you can join NCT07728123 on ClinicalTrials.gov

17. Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

    The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in adults with HIV-1 whose virus is well controlled on daily oral treatment…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Optimus Medical Group, San Francisco, California

    Locations

    19 in total

    Run by

    Gilead Sciences

    See if you can join NCT07682961 on ClinicalTrials.gov

18. First Time in Human Study of Long Acting VH4524184 Formulations

    The purpose of this study is to identify 1 or more doses of parenterally administered VH4524184 that are safe, well tolerated and yield a PK drug exposure profile necessary to deliver a long-acting antiretroviral therapy for the treatment of HIV-1 infection.

    Stage

    Phase 1

    Ages

    18 to 55

    Site

    GSK Investigational Site, Lenexa, Kansas

    Locations

    3 in total

    Run by

    ViiV Healthcare

    See if you can join NCT06310551 on ClinicalTrials.gov

19. A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)

    This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection. The study is comparing two different doses of VH4524184, each taken with the medications emtricitabine and tenofovir alafenamide (FTC…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    GSK Investigational Site, Bakersfield, California

    Locations

    123 in total

    Run by

    ViiV Healthcare

    See if you can join NCT07202546 on ClinicalTrials.gov

20. A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

    VH4770359 (also known as GSK4770359) is an antiretroviral compound. This first-in-human study aims to evaluate the safety, tolerability, and pharmacokinetics (PK) of orally administered VH4770359 in healthy participants. The findings from this study will support the design of future clinical studie…

    Stage

    Phase 1

    Ages

    18 to 55

    Site

    GSK Investigational Site, Baltimore, Maryland

    Run by

    ViiV Healthcare

    See if you can join NCT07525544 on ClinicalTrials.gov

21. Sexual Health Advocacy for Guys - a Text Messaging-based HIV Prevention Program for Guys Who Are Into Guys

    SHAG is a text messaging-based HIV prevention program designed for cisgender sexual minority boys and men 13-20 years of age across the United States. Investigators will test it against a control group that receives messages about healthy lifestyle.

    Stage

    Not phased

    Ages

    13 to 22

    Site

    Center for Innovative Public Health Research, San Clemente, California

    Locations

    2 in total

    Run by

    Center for Innovative Public Health Research

    See if you can join NCT06230367 on ClinicalTrials.gov

22. Texting to Reduce Human Immunodeficiency Virus (HIV) Risk

    This is a 3-year study to test the efficacy of a text message-based intervention program. Dental patients at 4 community health centers (n= 266) will be randomized to receive either text messages (TMs) regarding HIV prevention or TMs regarding overall wellness. Prior to enrolling the 266 participan…

    Stage

    Not phased

    Ages

    18 and older

    Site

    South End Community Health Center, Boston, Massachusetts

    Locations

    2 in total

    Run by

    Boston University

    See if you can join NCT06088277 on ClinicalTrials.gov

23. An Effectiveness Trial of the PrEP for WINGS Study

    (Effectiveness Aim 1) To test the comparative effectiveness of PreP for WINGS versus PrEP alone on primary outcomes of increasing PrEP initiation measured by self-report/medical records, recent adherence and longer-term adherence by self-report/medical records over the 6-month follow-up; and second…

    Stage

    Not phased

    Ages

    18 and older

    Site

    The Columbia Community Partnership for Health, New York, New York

    Run by

    Columbia University

    See if you can join NCT06853314 on ClinicalTrials.gov

24. Skeletal Muscle Energetics and Fatiguability in Older Individuals

    The investigators are studying whether metabolic abnormalities in calf (leg) muscle in older people with and others without HIV are associated with decreased abilities to exercise.

    Stage

    Not phased

    Ages

    60 to 90

    Site

    Johns Hopkins Hospital, Baltimore, Maryland

    Run by

    Johns Hopkins University

    See if you can join NCT04142047 on ClinicalTrials.gov

25. A Setting Focus Overdose Prevention Intervention

    A pilot injection-setting targeted peer-driven intervention to reduce HIV and hepatitis C virus transmission and overdose risk behaviors among people who inject drugs (PWID).

    Stage

    Not phased

    Ages

    18 and older

    Site

    Lighthouse Studies at Peer Point, Baltimore, Maryland

    Run by

    Johns Hopkins Bloomberg School of Public Health

    See if you can join NCT05320835 on ClinicalTrials.gov